StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA - Free Report) in a research note published on Thursday morning. The firm issued a hold rating on the biopharmaceutical company's stock.
Separately, HC Wainwright started coverage on Vanda Pharmaceuticals in a research report on Thursday, October 31st. They set a "buy" rating and a $18.00 price objective for the company.
Check Out Our Latest Research Report on VNDA
Vanda Pharmaceuticals Price Performance
VNDA stock traded up $0.08 during trading on Thursday, reaching $4.63. The company had a trading volume of 717,345 shares, compared to its average volume of 1,237,709. The business has a 50 day moving average of $4.85 and a 200 day moving average of $5.22. The company has a market cap of $269.97 million, a P/E ratio of -16.54 and a beta of 0.76. Vanda Pharmaceuticals has a 52 week low of $3.46 and a 52 week high of $6.75.
Insider Transactions at Vanda Pharmaceuticals
In related news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the transaction, the director now owns 44,857 shares in the company, valued at approximately $231,910.69. The trade was a 10.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 8.90% of the company's stock.
Institutional Trading of Vanda Pharmaceuticals
Large investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. bought a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter valued at approximately $39,000. ORG Wealth Partners LLC bought a new stake in Vanda Pharmaceuticals during the 3rd quarter valued at about $40,000. China Universal Asset Management Co. Ltd. lifted its holdings in Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 4,374 shares in the last quarter. SG Americas Securities LLC bought a new position in Vanda Pharmaceuticals in the 2nd quarter worth about $61,000. Finally, XTX Topco Ltd purchased a new position in shares of Vanda Pharmaceuticals during the second quarter worth approximately $75,000. Institutional investors own 88.14% of the company's stock.
About Vanda Pharmaceuticals
(
Get Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
See Also
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
